In premenopausal women, oestrogen receptor positive (ER+) disease constitutes over 80% of breast cancers.1 The vast majority of these patients will receive endocrine therapy, often by ovarian ablation, although ER status is an imperfect predictor of response to this therapy. This evidence concerns the gene ESR1 and breast carcinoma.